Copper Peptide (GHK-Cu): A Literature Course on What Studies Report

Glycyl-L-histidyl-L-lysine, usually shortened to GHK, is a tripeptide that binds copper(II) with high affinity to form the complex written as GHK-Cu. It appears in the published literature under several labels — copper peptide, copper tripeptide, GHK-Cu — and it has been studied in skin biology, wound repair, gene-expression profiling and, more recently, in materials science as a building block for hydrogels. This page is a reading guide to that literature. It describes what researchers reported in specific papers, where the evidence sits on the scale from cell culture to human trial, and where the cited papers themselves flagged limitations.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision or health condition. Nothing here is a protocol, a regimen or a suggestion to use any substance.

What GHK-Cu Is, According to the Literature

GHK is a short peptide sequence that reviews describe as occurring naturally in human plasma, with a strong affinity for copper ions. A 2018 review in International Journal of Molecular Sciences framed GHK-Cu as a molecule with regenerative and protective actions and examined it specifically in the light of gene-expression data (Pickart and Margolina, 2018). A 2020 review in Aging Pathobiology and Therapeutics approached the same peptide from the angle of biological ageing, describing its potential as an anti-aging peptide and summarising the mechanistic claims that had accumulated around it (Pickart and colleagues, 2020).

Two structural facts drive most of the research interest. First, the histidine and lysine residues create a copper-binding site, so the peptide behaves as a copper delivery and chelation system rather than as a peptide acting alone. Second, the molecule is small, which matters for the formulation debates discussed later in this page — small enough to be interesting for topical delivery, but still charged and hydrophilic in ways that a 2025 review in BioImpacts described as creating real problems for skin penetration (the review on topically applied GHK as an anti-wrinkle peptide).

How to read the evidence base

Most published GHK-Cu work sits in three tiers, and mixing them up is the most common error readers make:

• In vitro and gene-expression work — cell cultures, transcriptome analyses, mechanistic assays. The 2018 review drew heavily on this tier (Pickart and Margolina, 2018).
• Animal models — rodent studies of wound healing, lung injury and muscle function, several of which are cited below.
• Human data — largely topical cosmetic formulation studies; reviews of injectable peptide therapy describe the human clinical evidence base for injected peptides as thin (the 2026 primer for orthopaedic and sports medicine physicians).

Gene Expression and Mechanism: What Studies Report

The most distinctive line of GHK research is transcriptomic. The 2018 IJMS review examined GHK-Cu against new gene data and organised the peptide's reported regenerative and protective actions around patterns of gene modulation rather than around a single receptor or pathway (Pickart and Margolina, 2018). The 2020 ageing-focused review covered overlapping ground, arguing that the breadth of reported gene-level activity was the basis for calling GHK a candidate anti-aging peptide (Pickart and colleagues, 2020).

Two more recent animal papers identified specific molecular targets rather than broad expression signatures. A 2024 study in Redox Biology reported that the GHK-Cu complex attenuated lung inflammation and fibrosis in a silicosis model by targeting peroxiredoxin 6 (the silicosis study). A 2023 study in the Journal of Cachexia, Sarcopenia and Muscle reported that GHK-Cu rescued cigarette-smoking-induced skeletal muscle dysfunction through a sirtuin 1-dependent pathway (the skeletal muscle study). Both are preclinical, and both describe mechanisms — peroxiredoxin 6, SIRT1 — that sit in antioxidant and stress-response biology rather than in the collagen-synthesis story that dominates cosmetic marketing.

Why copper matters to the mechanism

Because GHK-Cu is a copper complex, some reported activity may reflect copper handling as much as the peptide backbone. A 2024 paper in Angewandte Chemie used copper-induced supramolecular peptide assemblies to trigger multi-pathway cell death and tumour inhibition, illustrating that copper-peptide chemistry can be engineered toward cytotoxic ends in an oncology model rather than regenerative ones (the copper-induced assembly study). That paper is not about skincare, but it is a useful corrective: the same metal-peptide coordination chemistry produces very different biology depending on concentration, assembly state and context.

Skin, Wrinkles and Topical Formulation

The largest consumer-facing use of copper peptide is topical. The 2025 BioImpacts review is the most directly relevant paper in the verified set: it examined topically applied GHK as an anti-wrinkle peptide and set out advantages, problems and prospects (the topical GHK review). Its framing matters. Rather than simply endorsing topical GHK, the review treated delivery as the central unsolved problem — a peptide that performs in cell culture still has to cross the stratum corneum in a stable, copper-bound form to do anything in skin.

Readers evaluating cosmetic claims can use that review as a checklist of questions: was the formulation characterised, was penetration measured, was the copper complex stable in the vehicle, and were outcomes objective or self-reported? The review's own conclusion — that problems remain alongside the advantages (the topical GHK review) — is a more accurate summary of the state of the field than most product copy.

Wound Healing and Biomaterials

Some of the most technically detailed recent GHK-Cu work is not about the free peptide at all but about copper-peptide materials. A 2025 paper in Biomaterials Research described a food-derived tripeptide-copper self-healing hydrogel developed for infected wound healing, combining the copper complex with a gel matrix that reformed after damage (the self-healing hydrogel study). A 2025 paper in Nature Communications reported that a hydrogel incorporating a dimeric copper peptide promoted diabetic wound healing in a preclinical model (the dimeric copper peptide study).

Both are worth reading carefully for one structural reason: the active entity in each is a construct, not a solution of GHK-Cu. The dimeric version in the Nature Communications paper is chemically distinct from monomeric GHK-Cu (the dimeric copper peptide study), and the hydrogel in the Biomaterials Research paper delivers the complex in a sustained, localised way that a simple topical or injected preparation does not replicate (the self-healing hydrogel study). Findings from engineered delivery systems do not transfer automatically to unformulated peptide.

Sports Medicine and Injectable Peptide Reviews

GHK-Cu appears in a cluster of recent clinical reviews that examined peptides being used outside approved indications. A 2026 primer in The American Journal of Sports Medicine surveyed injectable peptide therapy for orthopaedic and sports medicine physicians, describing the category and the gap between preclinical enthusiasm and controlled human data (the injectable peptide primer). A companion 2026 review in the same journal covered peptide supplements and their therapeutic applications in sports medicine (the peptide supplements review).

A 2026 Sports Medicine review examined the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, explicitly separating agents with regulatory approval from those circulating without it (the safety and efficacy review). A 2026 review in JAAOS Global Research & Reviews covered therapeutic peptides in orthopaedics, including applications, challenges and future directions (the orthopaedic peptides review). Collectively, these reviews are the best available orientation to how clinicians currently categorise peptides like GHK-Cu: interesting preclinical profiles, incomplete human safety and efficacy datasets, and a regulatory status that differs sharply from that of approved drugs.

Regulatory framing described in the literature

The 2026 Sports Medicine review's distinction between approved and unapproved peptide therapies is the key regulatory point it raises (the safety and efficacy review). Many peptides discussed in that literature are supplied as research chemicals rather than as approved medicines, and the orthopaedic reviews described the resulting gaps in standardisation and oversight as a challenge for the field (the orthopaedic peptides review). This page does not offer legal advice.

Adverse Events: What Studies Report

The verified literature on GHK-Cu is weighted toward mechanism and efficacy, not toward systematic safety surveillance, and that imbalance is itself a finding. The most direct safety-focused source is the 2026 Sports Medicine review of approved and unapproved peptide therapies, which addressed safety alongside efficacy for musculoskeletal and performance uses and treated the unapproved category as carrying unresolved safety questions (the safety and efficacy review). The 2026 injectable peptide primer similarly framed clinician awareness of injectable peptide use as a safety issue in its own right (the injectable peptide primer).

For topical use, the 2025 BioImpacts review discussed problems as well as advantages of topically applied GHK, situating tolerability and formulation stability among the unresolved issues (the topical GHK review). Separately, the 2024 Angewandte Chemie work is a reminder that copper-peptide assemblies were deliberately engineered to induce multi-pathway cell death in a tumour-inhibition context (the copper-induced assembly study) — copper biology is dose- and context-dependent, not uniformly benign. Anyone evaluating risk should read the primary safety discussions in these papers rather than relying on summaries.

Dosing: What the Verified Literature Supports

No dose figures are reproduced on this page. The verified papers cited here are predominantly reviews, mechanistic animal studies and biomaterials reports whose abstract-level content does not establish human dosing, and the clinical reviews explicitly characterise the human evidence base for peptides in this category as incomplete (the safety and efficacy review) (the injectable peptide primer). Concentrations used in a hydrogel applied to a rodent wound (the dimeric copper peptide study) are not translatable to any other route or species, and the study authors did not present them as such.

How to Read a GHK-Cu Paper: A Short Method

1. Identify the exact molecule. Free GHK, GHK-Cu, a dimeric copper peptide (the dimeric copper peptide study) and a copper-peptide supramolecular assembly (the copper-induced assembly study) are different entities.
2. Identify the model. Silicosis lung tissue (the silicosis study) and smoke-exposed skeletal muscle (the skeletal muscle study) are disease-specific models, not general wellness models.
3. Identify the route. Topical delivery carries its own unresolved problems (the topical GHK review).
4. Separate review from primary data. The 2018 and 2020 reviews synthesise; they are starting points for locating primary studies (2018 review) (2020 review).
5. Check the regulatory framing. Orthopaedic reviews describe applications and challenges together (the orthopaedic peptides review).

Open Questions in the Literature

Several questions recur across the cited papers and remain unresolved. Whether transcriptome-level activity described in reviews (2018 review) translates into clinically measurable outcomes in humans is the largest. Whether topical formulations can deliver an intact copper complex to the dermis at meaningful levels is the central formulation question raised by the 2025 review (the topical GHK review). Whether preclinical results in fibrosis and muscle models (the silicosis study) (the skeletal muscle study) justify human trials is a question the authors of those papers raised themselves. And whether peptides used outside approved indications can be characterised for safety at all, absent controlled trials, is the framing problem the 2026 sports medicine reviews returned to repeatedly (the peptide supplements review) (the safety and efficacy review).

Readers who want to go further should read the abstracts linked below in full, then follow the reference lists of the two 2026 orthopaedic reviews, which are the most current maps of the clinical evidence landscape for peptides in this class.

References

• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018)
• The potential of GHK as an anti-aging peptide (Aging Pathobiology and Therapeutics, 2020)
• Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective (BioImpacts, 2025)
• Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing (Biomaterials Research, 2025)
• Dimeric copper peptide incorporated hydrogel for promoting diabetic wound healing (Nature Communications, 2025)
• Glycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway (Journal of Cachexia, Sarcopenia and Muscle, 2023)
• The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6 (Redox Biology, 2024)
• Copper-Induced Supramolecular Peptide Assemblies for Multi-Pathway Cell Death and Tumor Inhibition (Angewandte Chemie International Edition, 2024)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine (The American Journal of Sports Medicine, 2026)